PTEN and neuroblastoma: The aim of this study was to evaluate the role of PTEN/PI-3K and the BRD4/MYCN signaling axis and a “first in class” dual PI-3K/BRD4 inhibitor, SF1126 as biomarkers and a therapeutic strategy, respectively for the treatment of MYCN dependent high risk neuroblastoma.